Pharma
-
Novo Nordisk Targets Australian Market for Wegovy Pill Expansion
Following its UK debut, Novo Nordisk is eyeing an Australian launch for its oral weight-loss drug Wegovy, pending local regulatory approval.
-
Apotex Health Prices Upsized IPO at $1.3 Billion, Marking Landmark TSX Debut
Canadian pharmaceutical giant Apotex Health has successfully priced its IPO at $24 per share, raising $1.3 billion and signaling a major resurgence for the Toronto Stock Exchange.
-
Novo Nordisk Hikes Guidance as Wegovy Pill Sales Outpace Rivals
Novo Nordisk has raised its 2026 outlook following a strong debut for the Wegovy oral tablet in the U.S. market, signaling a pivotal shift in the competitive landscape for obesity treatments.
-
Eli Lilly Stock Faces ‘Reduce’ Warning Amid Mixed Data
Eli Lilly stock navigates a volatile week as positive clinical data meets a sharp analyst downgrade, sparking debate over the future of the obesity drug market.
-
Novo Nordisk Stock Falls on Disappointing CagriSema Trial Results
Novo Nordisk A/S (NVO) shares dropped pre-market after its experimental obesity drug, CagriSema, failed to meet its primary endpoint in a Phase 3 trial, impacting its competitive standing.